Literature DB >> 17199454

Treatment considerations in women with schizophrenia.

Deanna L Kelly1.   

Abstract

Schizophrenia is a challenging and complex psychiatric disorder. It is a chronic disorder of thought, affect, and cognition that significantly disturbs the individual's ability to function in society and develop interpersonal relationships. The clinical presentation can be extremely varied, with symptoms including delusional thinking, disorganized thoughts and speech, hallucinatory behavior, and negative symptoms (e.g., blunted affect, avolition, alogia, anhedonia). Approximately 1% of the population is affected by schizophrenia worldwide, and women may experience different symptoms, have a later age of onset, may respond to different treatments, and may be more concerned about specific side effects than men. Women with schizophrenia traditionally have been treated in the same way as men and have generally had poorer comprehensive medical care. With the introduction of many new antipsychotic medications in recent years, this review focuses on sex differences in schizophrenia, with an emphasis on differences in treatment and side effects. Additionally, it presents patient counseling issues in sexuality and health outcomes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17199454     DOI: 10.1089/jwh.2006.15.1132

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  5 in total

1.  The impact of substance abuse on osteoporosis screening and risk of osteoporosis in women with psychotic disorders.

Authors:  D L Kelly; C S Myers; M T Abrams; S Feldman; J Park; R P McMahon; J-C Shim
Journal:  Osteoporos Int       Date:  2010-06-09       Impact factor: 4.507

Review 2.  Emotional response deficits in schizophrenia: insights from affective science.

Authors:  Ann M Kring; Erin K Moran
Journal:  Schizophr Bull       Date:  2008-06-25       Impact factor: 9.306

3.  Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial.

Authors:  Deanna L Kelly; Megan M Powell; Heidi J Wehring; MacKenzie A Sayer; Ann Marie Kearns; Ann L Hackman; Robert W Buchanan; Rebecca B Nichols; Heather A Adams; Charles M Richardson; Gopal Vyas; Robert P McMahon; Amber K Earl; Kelli M Sullivan; Fang Liu; Sarah E Luttrell; Faith B Dickerson; Stephanie M Feldman; Supriya Narang; Maju M Koola; Peter F Buckley; Jill A RachBeisel; Joseph P McEvoy
Journal:  J Clin Psychopharmacol       Date:  2018-08       Impact factor: 3.153

4.  Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).

Authors:  Deanna L Kelly; Heidi J Wehring; Amber K Earl; Kelli M Sullivan; Faith B Dickerson; Stephanie Feldman; Robert P McMahon; Robert W Buchanan; Dale Warfel; William R Keller; Bernard A Fischer; Joo-Cheol Shim
Journal:  BMC Psychiatry       Date:  2013-08-22       Impact factor: 3.630

5.  Schizophrenia clinical symptom differences in women vs. men with and without a history of childhood physical abuse.

Authors:  Deanna L Kelly; Laura M Rowland; Kathleen M Patchan; Kelli Sullivan; Amber Earl; Heather Raley; Fang Liu; Stephanie Feldman; Robert P McMahon
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2016-03-03       Impact factor: 3.033

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.